Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05918666Active Not Recruiting

National Register of Actionable Mutations

Role: lead

NCT04460807Phase 3Terminated

Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Role: collaborator

NCT06235268Unknown

Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Role: lead

All 3 trials loaded